New autoimmune diseases after cord blood transplantation: A retrospective study of EUROCORD and the autoimmune disease working party of the European group for blood and marrow transplantation

Thomas Daikeler, Myriam Labopin, Annalisa Ruggeri, Alessandro Crotta, Mario Abinun, Ayad Ahmed Hussein, Kristina Carlson, Jérôme Cornillon, Jose L. Diez-Martin, Virginie Gandemer, Maura Faraci, Caroline Lindemans, Anne O'Meara, Valerie Mialou, Marleen Renard, Petr Sedlacek, Anne Sirvent, Gérard Socié, Federica Sora, Stefania VarottoJaime Sanz, Jan Voswinkel, Ajay Vora, M. Akif Yesilipek, Andree Laure Herr, Eliane Gluckman, Dominique Farge, Vanderson Rocha

Research output: Contribution to journalArticle

Abstract

To describe the incidence, risk factors, and treatment of autoimmune diseases (ADs) occurring after cord blood transplantation (CBT), we analyzed both CBT recipients reported to EUROCORD who had developed at least 1 new AD and those who had not. Fifty-two of 726 reported patients developed at least 1 AD within 212 days (range, 27-4267) after CBT. Cumulative incidence of ADs after CBT was 5.0% ± 1% at 1 year and 6.6% ± 1% at 5 years. Patients developing ADs were younger and had more nonmalignant diseases (P <.001). ADs target hematopoietic (autoimmune hemolytic anemia, n = 20; Evans syndrome, n = 9; autoimmune thrombocytopenia, n = 11; and immune neutropenia, n = 1) and other tissues (thyroiditis, n = 3; psoriasis, n = 2; Graves disease, n = 1; membranous glomerulonephritis, n = 2; rheumatoid arthritis, n = 1; ulcerative colitis, n = 1; and systemic lupus erythematosus, n = 1). Four patients developed 2 ADs (3 cases of immune thrombocytopenia followed by autoimmune hemolytic anemia and 1 Evans syndrome with rheumatoid arthritis). By multivariate analysis, the main risk factor for developing an AD was nonmalignant disease as an indication for CBT (P = .0001). Hematologic ADs were most often treated with steroids, rituximab, and cyclosporine. With a median follow-up of 26 months (range, 2-91), 6 of 52 patients died as a consequence of ADs. We conclude that CBT may be followed by potentially life-threatening, mainly hematologic ADs.

Original languageEnglish
Pages (from-to)1059-1064
Number of pages6
JournalBlood
Volume121
Issue number6
DOIs
Publication statusPublished - Feb 7 2013

Fingerprint

Blood Group Antigens
Fetal Blood
Autoimmune Diseases
Blood
Retrospective Studies
Transplantation
Bone Marrow
Autoimmune Hemolytic Anemia
Idiopathic Thrombocytopenic Purpura
Hematologic Diseases
Rheumatoid Arthritis
Thyroiditis
Membranous Glomerulonephritis
Graves Disease
Incidence
Neutropenia
Ulcerative Colitis
Psoriasis
Systemic Lupus Erythematosus
Cyclosporine

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

New autoimmune diseases after cord blood transplantation : A retrospective study of EUROCORD and the autoimmune disease working party of the European group for blood and marrow transplantation. / Daikeler, Thomas; Labopin, Myriam; Ruggeri, Annalisa; Crotta, Alessandro; Abinun, Mario; Hussein, Ayad Ahmed; Carlson, Kristina; Cornillon, Jérôme; Diez-Martin, Jose L.; Gandemer, Virginie; Faraci, Maura; Lindemans, Caroline; O'Meara, Anne; Mialou, Valerie; Renard, Marleen; Sedlacek, Petr; Sirvent, Anne; Socié, Gérard; Sora, Federica; Varotto, Stefania; Sanz, Jaime; Voswinkel, Jan; Vora, Ajay; Yesilipek, M. Akif; Herr, Andree Laure; Gluckman, Eliane; Farge, Dominique; Rocha, Vanderson.

In: Blood, Vol. 121, No. 6, 07.02.2013, p. 1059-1064.

Research output: Contribution to journalArticle

Daikeler, T, Labopin, M, Ruggeri, A, Crotta, A, Abinun, M, Hussein, AA, Carlson, K, Cornillon, J, Diez-Martin, JL, Gandemer, V, Faraci, M, Lindemans, C, O'Meara, A, Mialou, V, Renard, M, Sedlacek, P, Sirvent, A, Socié, G, Sora, F, Varotto, S, Sanz, J, Voswinkel, J, Vora, A, Yesilipek, MA, Herr, AL, Gluckman, E, Farge, D & Rocha, V 2013, 'New autoimmune diseases after cord blood transplantation: A retrospective study of EUROCORD and the autoimmune disease working party of the European group for blood and marrow transplantation', Blood, vol. 121, no. 6, pp. 1059-1064. https://doi.org/10.1182/blood-2012-07-445965
Daikeler, Thomas ; Labopin, Myriam ; Ruggeri, Annalisa ; Crotta, Alessandro ; Abinun, Mario ; Hussein, Ayad Ahmed ; Carlson, Kristina ; Cornillon, Jérôme ; Diez-Martin, Jose L. ; Gandemer, Virginie ; Faraci, Maura ; Lindemans, Caroline ; O'Meara, Anne ; Mialou, Valerie ; Renard, Marleen ; Sedlacek, Petr ; Sirvent, Anne ; Socié, Gérard ; Sora, Federica ; Varotto, Stefania ; Sanz, Jaime ; Voswinkel, Jan ; Vora, Ajay ; Yesilipek, M. Akif ; Herr, Andree Laure ; Gluckman, Eliane ; Farge, Dominique ; Rocha, Vanderson. / New autoimmune diseases after cord blood transplantation : A retrospective study of EUROCORD and the autoimmune disease working party of the European group for blood and marrow transplantation. In: Blood. 2013 ; Vol. 121, No. 6. pp. 1059-1064.
@article{d98ae179b8984257889de151a7560204,
title = "New autoimmune diseases after cord blood transplantation: A retrospective study of EUROCORD and the autoimmune disease working party of the European group for blood and marrow transplantation",
abstract = "To describe the incidence, risk factors, and treatment of autoimmune diseases (ADs) occurring after cord blood transplantation (CBT), we analyzed both CBT recipients reported to EUROCORD who had developed at least 1 new AD and those who had not. Fifty-two of 726 reported patients developed at least 1 AD within 212 days (range, 27-4267) after CBT. Cumulative incidence of ADs after CBT was 5.0{\%} ± 1{\%} at 1 year and 6.6{\%} ± 1{\%} at 5 years. Patients developing ADs were younger and had more nonmalignant diseases (P <.001). ADs target hematopoietic (autoimmune hemolytic anemia, n = 20; Evans syndrome, n = 9; autoimmune thrombocytopenia, n = 11; and immune neutropenia, n = 1) and other tissues (thyroiditis, n = 3; psoriasis, n = 2; Graves disease, n = 1; membranous glomerulonephritis, n = 2; rheumatoid arthritis, n = 1; ulcerative colitis, n = 1; and systemic lupus erythematosus, n = 1). Four patients developed 2 ADs (3 cases of immune thrombocytopenia followed by autoimmune hemolytic anemia and 1 Evans syndrome with rheumatoid arthritis). By multivariate analysis, the main risk factor for developing an AD was nonmalignant disease as an indication for CBT (P = .0001). Hematologic ADs were most often treated with steroids, rituximab, and cyclosporine. With a median follow-up of 26 months (range, 2-91), 6 of 52 patients died as a consequence of ADs. We conclude that CBT may be followed by potentially life-threatening, mainly hematologic ADs.",
author = "Thomas Daikeler and Myriam Labopin and Annalisa Ruggeri and Alessandro Crotta and Mario Abinun and Hussein, {Ayad Ahmed} and Kristina Carlson and J{\'e}r{\^o}me Cornillon and Diez-Martin, {Jose L.} and Virginie Gandemer and Maura Faraci and Caroline Lindemans and Anne O'Meara and Valerie Mialou and Marleen Renard and Petr Sedlacek and Anne Sirvent and G{\'e}rard Soci{\'e} and Federica Sora and Stefania Varotto and Jaime Sanz and Jan Voswinkel and Ajay Vora and Yesilipek, {M. Akif} and Herr, {Andree Laure} and Eliane Gluckman and Dominique Farge and Vanderson Rocha",
year = "2013",
month = "2",
day = "7",
doi = "10.1182/blood-2012-07-445965",
language = "English",
volume = "121",
pages = "1059--1064",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "6",

}

TY - JOUR

T1 - New autoimmune diseases after cord blood transplantation

T2 - A retrospective study of EUROCORD and the autoimmune disease working party of the European group for blood and marrow transplantation

AU - Daikeler, Thomas

AU - Labopin, Myriam

AU - Ruggeri, Annalisa

AU - Crotta, Alessandro

AU - Abinun, Mario

AU - Hussein, Ayad Ahmed

AU - Carlson, Kristina

AU - Cornillon, Jérôme

AU - Diez-Martin, Jose L.

AU - Gandemer, Virginie

AU - Faraci, Maura

AU - Lindemans, Caroline

AU - O'Meara, Anne

AU - Mialou, Valerie

AU - Renard, Marleen

AU - Sedlacek, Petr

AU - Sirvent, Anne

AU - Socié, Gérard

AU - Sora, Federica

AU - Varotto, Stefania

AU - Sanz, Jaime

AU - Voswinkel, Jan

AU - Vora, Ajay

AU - Yesilipek, M. Akif

AU - Herr, Andree Laure

AU - Gluckman, Eliane

AU - Farge, Dominique

AU - Rocha, Vanderson

PY - 2013/2/7

Y1 - 2013/2/7

N2 - To describe the incidence, risk factors, and treatment of autoimmune diseases (ADs) occurring after cord blood transplantation (CBT), we analyzed both CBT recipients reported to EUROCORD who had developed at least 1 new AD and those who had not. Fifty-two of 726 reported patients developed at least 1 AD within 212 days (range, 27-4267) after CBT. Cumulative incidence of ADs after CBT was 5.0% ± 1% at 1 year and 6.6% ± 1% at 5 years. Patients developing ADs were younger and had more nonmalignant diseases (P <.001). ADs target hematopoietic (autoimmune hemolytic anemia, n = 20; Evans syndrome, n = 9; autoimmune thrombocytopenia, n = 11; and immune neutropenia, n = 1) and other tissues (thyroiditis, n = 3; psoriasis, n = 2; Graves disease, n = 1; membranous glomerulonephritis, n = 2; rheumatoid arthritis, n = 1; ulcerative colitis, n = 1; and systemic lupus erythematosus, n = 1). Four patients developed 2 ADs (3 cases of immune thrombocytopenia followed by autoimmune hemolytic anemia and 1 Evans syndrome with rheumatoid arthritis). By multivariate analysis, the main risk factor for developing an AD was nonmalignant disease as an indication for CBT (P = .0001). Hematologic ADs were most often treated with steroids, rituximab, and cyclosporine. With a median follow-up of 26 months (range, 2-91), 6 of 52 patients died as a consequence of ADs. We conclude that CBT may be followed by potentially life-threatening, mainly hematologic ADs.

AB - To describe the incidence, risk factors, and treatment of autoimmune diseases (ADs) occurring after cord blood transplantation (CBT), we analyzed both CBT recipients reported to EUROCORD who had developed at least 1 new AD and those who had not. Fifty-two of 726 reported patients developed at least 1 AD within 212 days (range, 27-4267) after CBT. Cumulative incidence of ADs after CBT was 5.0% ± 1% at 1 year and 6.6% ± 1% at 5 years. Patients developing ADs were younger and had more nonmalignant diseases (P <.001). ADs target hematopoietic (autoimmune hemolytic anemia, n = 20; Evans syndrome, n = 9; autoimmune thrombocytopenia, n = 11; and immune neutropenia, n = 1) and other tissues (thyroiditis, n = 3; psoriasis, n = 2; Graves disease, n = 1; membranous glomerulonephritis, n = 2; rheumatoid arthritis, n = 1; ulcerative colitis, n = 1; and systemic lupus erythematosus, n = 1). Four patients developed 2 ADs (3 cases of immune thrombocytopenia followed by autoimmune hemolytic anemia and 1 Evans syndrome with rheumatoid arthritis). By multivariate analysis, the main risk factor for developing an AD was nonmalignant disease as an indication for CBT (P = .0001). Hematologic ADs were most often treated with steroids, rituximab, and cyclosporine. With a median follow-up of 26 months (range, 2-91), 6 of 52 patients died as a consequence of ADs. We conclude that CBT may be followed by potentially life-threatening, mainly hematologic ADs.

UR - http://www.scopus.com/inward/record.url?scp=84873593450&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873593450&partnerID=8YFLogxK

U2 - 10.1182/blood-2012-07-445965

DO - 10.1182/blood-2012-07-445965

M3 - Article

C2 - 23247725

AN - SCOPUS:84873593450

VL - 121

SP - 1059

EP - 1064

JO - Blood

JF - Blood

SN - 0006-4971

IS - 6

ER -